Corticosteroid-induced leukocytosis

      Usually no treatment is necessary. Spontaneous remission occurs in

Glucocorticoid therapy is associated with an appreciable risk of bone loss, which is most pronounced in the first few months of use. In addition, glucocorticoids increase fracture risk, and fractures occur at higher bone mineral density (BMD) values than occur in postmenopausal osteoporosis. The increased risk of fracture has been reported with doses of prednisone or its equivalent as low as to mg daily [ 1 ]. Thus, glucocorticoid-induced bone loss should be treated aggressively, particularly in those already at high risk for fracture (older age, prior fragility fracture). In other individuals, clinical risk factor and bone density assessment may help guide therapy. The prevention and treatment of glucocorticoid-induced bone loss will be reviewed here. The clinical features are reviewed separately. (See "Clinical features and evaluation of glucocorticoid-induced osteoporosis" .)

Corticosteroid-induced leukocytosis

corticosteroid-induced leukocytosis

Media:

corticosteroid-induced leukocytosiscorticosteroid-induced leukocytosiscorticosteroid-induced leukocytosiscorticosteroid-induced leukocytosiscorticosteroid-induced leukocytosis

http://buy-steroids.org